Immunwork, Inc., founded in 2014, was a subsidiary of T-E Pharma Holding, focused on the development of innovative platforms and novel drugs.  Utilizing the fatty acid bundle platform, we have developed the ultra-long-acting drug candidates for the treatment of critical endocrine diseases, such as diabetes, obesity, acromegaly and neuroendocrine tumors.

Two promising candidates are currently in human clinical trial stage, demonstrating excellent tolerability and no significant adverse effects. These advancements highlight the potential of our platform to revolutionize drug development, offering superior treatments with improved patient outcomes.